Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future approaches for treating hematologic disease.

M Reff1, G Braslawsky, N Hanna

  • 1IDEC Pharmaceuticals Corporation, San Diego, CA 92191-9080, USA. mreff@idecpharm.com

Current Pharmaceutical Biotechnology
|January 5, 2002
PubMed
Summary

Monoclonal antibodies show promise in treating hematologic malignancies and other cancers by inhibiting tumor growth and activating immune responses. Advances in antibody engineering enhance their efficacy and targeting capabilities for future cancer therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomised trial of a trauma-informed well-being program to promote mental health in adolescents with type 1 diabetes: Study protocol.

Diabetic medicine : a journal of the British Diabetic Association·2025
Same author

Interpretation and classification of FBN1 variants associated with Marfan syndrome: consensus recommendations from the Clinical Genome Resource's FBN1 variant curation expert panel.

Genome medicine·2024
Same author

De Novo Balanced Translocations Disrupting the FBN1 Gene Diagnosed by Genome Sequencing: An Uncommon Cause of Marfan Syndrome Modifying Genetic Counseling.

American journal of medical genetics. Part A·2024
Same author

Canadian Surgery Forum 2018: St. John's, NL Sept. 13-15, 2018.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

2021 Canadian Surgery Forum: Virtual, online Sept. 21-24, 2021.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Diagnostic accuracy of a calibrated abdominal compression to predict fluid responsiveness in children.

British journal of anaesthesia·2018

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Monoclonal antibodies (mAbs) are increasingly recognized for their therapeutic potential in cancer treatment.
  • Approved mAbs like Rituxan, Mylotarg, and Campath have renewed interest in antibody-based therapies for hematologic malignancies.

Purpose of the Study:

  • To review the current and future applications of monoclonal antibodies in cancer therapy.
  • To highlight the role of antibody engineering in improving therapeutic efficacy and safety.

Main Methods:

  • Review of existing literature on monoclonal antibody therapy in oncology.
  • Discussion of advancements in antibody engineering techniques.
  • Exploration of potential future targets and antibody-based treatment strategies.

Related Experiment Videos

Main Results:

  • Monoclonal antibodies demonstrate efficacy through direct tumor cell inhibition, apoptosis induction, and host immune activation.
  • Antibody engineering allows for reduced immunogenicity, modulated half-life, enhanced effector functions, and improved tumor targeting.
  • mAbs can be used as monotherapy, drug/radionuclide delivery agents, or in combination with chemotherapy.

Conclusions:

  • Monoclonal antibodies represent a versatile and effective therapeutic modality for various cancers.
  • Ongoing advancements in antibody engineering and target identification promise more sophisticated and personalized antibody-based cancer treatments.
  • Future research will focus on novel targets and engineered antibodies for agonist/antagonist activity and enhanced effector mechanisms.